Peptide Chemistry Techniques in the Manufacture of Radionuclide Products
Steve McIntyre
Peptide Process Development Department Manager, Almac Group
Peptide precursors are increasingly present in the world of targeted radiopharmaceuticals used for diagnosis, therapy, or a combination thereof. Usually low scale and highly customised, these molecules necessitate specific approaches both in manufacturing and analysis. Drawing from Almac’s success in accompanying such projects throughout clinical development, validation and commercial launch, this overview aims at raising awareness of the bespoke CMC requirements for radiotherapeutic agents and radiotracers.
Steve has the responsibility for process development and cGMP manufacture of large molecules at Almac, including peptides, peptide conjugates and imaging agents. He has worked in the pharmaceutical industry as a process development chemist since 1992, initially in small molecule chemistry before switching to peptide chemistry approximately 12 years ago. He studied at the University of Glasgow and the University of Basel.